Acute myeloid leukemia with unreported translocation (x; 3) (q24; p13): A case report-Reference-Cited by-同舟云学术

Acute myeloid leukemia with unreported translocation (x; 3) (q24; p13): A case report

Published:2024-02 Issue:2 Volume:12 Page:
ISSN:2050-0904
Container-title:Clinical Case Reports
language:en
Short-container-title:Clinical Case Reports

Author:

Gholami Nasrin¹^ORCID,Khalaji Amirreza²³^ORCID,Mehri Maghsood¹⁴,Mehrtabar Saba³⁵^ORCID,Habibzade Elham⁶^ORCID

Affiliation:

1. Hematology and Oncology Research Center Tabriz University of Medical Sciences Tabriz Iran

2. Connective Tissue Diseases Research Center Tabriz University of Medical Sciences Tabriz Iran

3. Immunology Research Center Tabriz University of Medical Sciences Tabriz Iran

4. Department of Medical Genetics Tabriz University of Medical Sciences Tabriz Iran

5. Student Research Committee Tabriz University of Medical Sciences Tabriz Iran

6. Faculty of Medicine Tabriz University of Medical Sciences Tabriz Iran

Abstract

Key Clinical MessageNovel and rare chromosomal aberrations in AML are important to understand, particularly if associated with tumorigenesis and how they contribute to prognostic risk. It is important that acute leukemia be treated right away. Herein, novel (x; 3) (q24; p13) is described.AbstractAcute myeloid leukemia (AML) is a cancer of the blood and bone marrow. It is the most common type of acute leukemia in adults. This type of cancer usually gets worse quickly if it is not treated. Here, we report an unusual case of AML with an unreported translocation associated with AML.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccr3.8543

Reference30 articles.

1. ‘Acute myeloid leukemia: a comprehensive review and 2016 update’

2. Implications of mutation profiling in myeloid malignancies‐PART 1: myelodysplastic syndromes and acute myeloid leukemia;Tremblay D;Oncology (Williston Park),2018

3. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

4. The preferential occurrence ofFLT3-TKD mutations in inv(16) AML and impact on survival outcome: a combined analysis of 1053 core-binding factor AML patients